AGMB
AgomAb Therapeutics NV
Price Chart
Latest Quote
$13.54
+0.37 (+2.81%)
Current Price
| Previous Close | $13.17 |
| Open | $12.90 |
| Day High | $13.99 |
| Day Low | $12.62 |
| Volume | 241,314 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 49.25M |
| Total Debt | $1.32M |
| Cash Equivalents | $291.81M |
| Net Income | $-94.50M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $666.82M |
| EPS (TTM) | $-1.57 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $474.05M |
| Income | $-94.50M |
| Book/sh | $2.63 |
| Cash/sh | $5.12 |
| Employees | 62 |
Financial Ratios
| Quick Ratio | 12.55 |
| Current Ratio | 12.88 |
| Debt/Eq | 0.43 |
Returns & Margins
Ownership
| Insider Ownership | 5.90% |
| Institutional Ownership | 53.64% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.54 |
| P/B | 5.15 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $37.67 |
Technical Indicators
| SMA20 | $13.88 |
| SMA50 | $13.22 |
| RSI | 39.14 |
| ATR | 0.9493 |
| Shares Float | 11.45M |
| Short Float | 2.31% |
| Short Ratio | 10.22 |
| Rel Volume | 1.89 |
Performance History
| Week | +5.62% |
| Month | +5.21% |
| Quarter | +18.36% |
| 6 Months | -16.47% |
| YTD | -7.58% |
| 10 Years | -7.58% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-09-01 | $13.54 | 241,300 |
| 2026-08-31 | $13.17 | 105,400 |
| 2026-08-27 | $13.84 | 154,200 |
| 2026-08-26 | $14.28 | 243,700 |
| 2026-08-25 | $14.02 | 219,300 |
| 2026-08-24 | $12.82 | 31,700 |
| 2026-08-21 | $13.25 | 68,400 |
| 2026-08-20 | $13.43 | 92,200 |
| 2026-08-19 | $13.75 | 137,400 |
| 2026-08-18 | $13.73 | 30,900 |
| 2026-08-17 | $13.68 | 119,300 |
| 2026-08-14 | $13.22 | 42,000 |
| 2026-08-13 | $13.95 | 241,600 |
| 2026-08-12 | $14.11 | 151,400 |
| 2026-08-11 | $14.85 | 61,000 |
| 2026-08-10 | $15.00 | 87,400 |
| 2026-08-07 | $14.50 | 367,400 |
| 2026-08-06 | $13.50 | 38,600 |
| 2026-08-05 | $14.32 | 29,100 |
| 2026-08-04 | $14.73 | 87,400 |
| 2026-08-03 | $13.52 | 126,000 |
About AgomAb Therapeutics NV
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFÃR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFÃR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
đ° Latest News
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?
Insider Monkey âĸ 2026-07-02T20:06:30Z
Agomab Therapeutics Shares NOV-ERA Phase 2b Study Design With Ontunisertib in Fibrostenosing Crohn's Disease
MT Newswires âĸ 2026-06-23T21:32:29ZAgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447
Insider Monkey âĸ 2026-04-12T18:46:47Z
European Equities Traded in the US as American Depositary Receipts Higher Wednesday
MT Newswires âĸ 2026-02-18T16:15:13ZAgomab indicated to open at $15.50, IPO priced at $16
TipRanks âĸ 2026-02-07T15:55:19Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $70,069 | $78,244 | $36,202 | $52,552 |
| Total Expenses | $69,222,234 | $56,079,644 | $36,424,150 | $26,432,325 |
| Rent Expense Supplemental | $246,409 | $159,991 | $207,871 | $142,473 |
| Other Income Expense | $-5,626,533 | $720,542 | $22,154,618 | $13,783,720 |
| Other Non Operating Income Expenses | $-5,672,077 | $990,307 | $22,146,444 | $13,884,153 |
| Net Non Operating Interest Income Expense | $1,805,442 | $1,332,477 | $245,241 | $29,195 |
| Total Other Finance Cost | $3,503 | $11,678 | $4,671 | $1,168 |
| Interest Expense Non Operating | $70,069 | $78,244 | $36,202 | $52,552 |
| Operating Expense | $69,222,234 | $56,079,644 | $36,424,150 | $26,432,325 |
| Other Operating Expenses | $-2,196,660 | $-1,195,843 | $-1,034,684 | $-1,034,684 |
| General And Administrative Expense | $14,681,770 | $11,470,279 | $7,003,387 | $5,243,489 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-73,043,325 | $-54,031,297 | $-13,301,413 | $-9,508,350 |
| Net Interest Income | $1,805,442 | $1,332,477 | $245,241 | $29,195 |
| Interest Income | $1,879,014 | $1,422,399 | $286,115 | $82,915 |
| Normalized Income | $-73,088,870 | $-53,828,973 | $-13,309,179 | $-9,447,086 |
| Net Income From Continuing And Discontinued Operation | $-73,043,325 | $-54,031,297 | $-13,301,413 | $-9,508,350 |
| Total Operating Income As Reported | $-69,222,234 | $-56,079,644 | $-36,424,150 | $-26,432,325 |
| Net Income Common Stockholders | $-73,043,325 | $-54,031,297 | $-13,301,413 | $-9,508,350 |
| Net Income | $-73,043,325 | $-54,031,297 | $-13,301,413 | $-9,508,350 |
| Net Income Including Noncontrolling Interests | $-73,043,325 | $-54,031,297 | $-13,301,413 | $-9,508,350 |
| Net Income Continuous Operations | $-73,043,325 | $-54,031,297 | $-13,301,413 | $-9,508,350 |
| Pretax Income | $-73,043,325 | $-54,026,625 | $-14,024,290 | $-12,619,409 |
| Interest Income Non Operating | $1,879,014 | $1,422,399 | $286,115 | $82,915 |
| Operating Income | $-69,222,234 | $-56,079,644 | $-36,424,150 | $-26,432,325 |
| Depreciation Amortization Depletion Income Statement | $255,751 | $363,190 | $115,614 | $26,860 |
| Depreciation And Amortization In Income Statement | $255,751 | $363,190 | $115,614 | $26,860 |
| Per Share | ||||
| Diluted EPS | $-1.50 | $-1.49 | $-0.37 | $-0.26 |
| Basic EPS | $-1.50 | $-1.49 | $-0.37 | $-0.26 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-67,441 | $409 | $-39,169 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-72,763,049 | $-53,315,426 | $-13,880,649 | $-12,439,565 |
| Total Unusual Items | $45,545 | $-269,765 | $8,175 | $-100,432 |
| Total Unusual Items Excluding Goodwill | $45,545 | $-269,765 | $8,175 | $-100,432 |
| Reconciled Depreciation | $255,751 | $363,190 | $115,614 | $26,860 |
| EBITDA (Bullshit earnings) | $-72,717,504 | $-53,585,191 | $-13,872,474 | $-12,539,997 |
| EBIT | $-72,973,256 | $-53,948,382 | $-13,988,088 | $-12,566,857 |
| Diluted Average Shares | $56,915,542 | $42,317,854 | $42,317,854 | $42,317,854 |
| Basic Average Shares | $56,915,542 | $42,317,854 | $42,317,854 | $42,317,854 |
| Diluted NI Availto Com Stockholders | $-73,043,325 | $-54,031,297 | $-13,301,413 | $-9,508,350 |
| Tax Provision | $0 | $4,671 | $-722,877 | $-3,111,059 |
| Gain On Sale Of Security | $45,545 | $-269,765 | $8,175 | $-100,432 |
| Other Taxes | $-597,921 | $-464,790 | $-386,547 | $-483,475 |
| Research And Development | $57,079,294 | $45,906,808 | $30,726,380 | $22,680,135 |
| Selling General And Administration | $14,681,770 | $11,470,279 | $7,003,387 | $5,243,489 |
| Other Gand A | $3,800,070 | $5,349,761 | $2,731,519 | $1,883,686 |
| Rent And Landing Fees | $246,409 | $159,991 | $207,871 | $142,473 |
| Salaries And Wages | $10,635,291 | $5,960,528 | $4,063,996 | $3,217,330 |
Fetched: 2026-08-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $119,327,337 | $186,101,831 | $143,306,082 | $43,823,426 |
| Total Assets | $179,500,172 | $240,987,968 | $199,998,829 | $117,943,476 |
| Total Non Current Assets | $37,917,785 | $37,969,169 | $37,119,000 | $34,929,347 |
| Non Current Accounts Receivable | $2,510,802 | $2,086,885 | $1,686,325 | $1,298,610 |
| Investmentin Financial Assets | $12,846 | $14,014 | $16,349 | $16,349 |
| Goodwill And Other Intangible Assets | $33,541,982 | $33,541,982 | $33,541,982 | $33,541,982 |
| Other Intangible Assets | $23,484,760 | $23,484,760 | $23,484,760 | $23,484,760 |
| Current Assets | $141,582,387 | $203,018,799 | $162,879,829 | $83,014,129 |
| Current Deferred Assets | $745,066 | $311,807 | $140,138 | $99,264 |
| Receivables | $4,770,524 | $2,474,600 | $19,795,632 | $3,888,824 |
| Other Receivables | $4,519,444 | $1,965,433 | $19,444,120 | $3,642,415 |
| Taxes Receivable | $233,563 | $444,938 | $171,669 | $85,250 |
| Notes Receivable | $17,517 | $64,230 | $179,844 | $161,158 |
| Cash Cash Equivalents And Short Term Investments | $136,066,797 | $200,232,392 | $142,942,892 | $79,026,041 |
| Cash And Cash Equivalents | $100,920,237 | $200,232,392 | $142,942,892 | $32,313,441 |
| Cash Equivalents | $0 | $169,333,175 | $0 | - |
| Cash Financial | $100,920,237 | $30,899,217 | $142,942,892 | $32,313,441 |
| Other Non Current Assets | - | - | $-1,168 | - |
| Other Current Assets | - | - | $1,168 | - |
| Debt | ||||
| Total Debt | $1,464,440 | $1,804,274 | $1,891,860 | $72,405 |
| Long Term Debt And Capital Lease Obligation | $1,173,654 | $1,485,461 | $1,680,486 | $42,041 |
| Current Debt And Capital Lease Obligation | $290,786 | $318,813 | $211,375 | $30,363 |
| Long Term Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $26,630,853 | $21,344,155 | $23,150,765 | $40,578,068 |
| Total Non Current Liabilities Net Minority Interest | $4,922,340 | $10,686,675 | $10,439,098 | $5,875,277 |
| Other Non Current Liabilities | $3,748,686 | $9,201,214 | $8,758,612 | $5,106,855 |
| Current Liabilities | $21,708,513 | $10,657,480 | $12,711,666 | $34,702,791 |
| Other Current Liabilities | $7,623,496 | - | $1,432,909 | $27,232,278 |
| Current Deferred Liabilities | $1,706,178 | $935,420 | $1,379,190 | $2,074,039 |
| Payables And Accrued Expenses | $12,088,053 | $9,403,246 | $9,688,193 | $5,366,110 |
| Payables | $9,218,732 | $7,157,538 | $8,212,075 | $4,628,051 |
| Total Tax Payable | $310,639 | $206,703 | $235,899 | $78,244 |
| Accounts Payable | $8,908,093 | $6,950,835 | $7,976,176 | $4,549,807 |
| Non Current Deferred Liabilities | - | - | $0 | $726,381 |
| Non Current Deferred Taxes Liabilities | - | - | $0 | $726,381 |
| Equity | ||||
| Common Stock Equity | $152,869,319 | $219,643,813 | $176,848,065 | $77,365,408 |
| Total Equity Gross Minority Interest | $152,869,319 | $219,643,813 | $176,848,065 | $77,365,408 |
| Stockholders Equity | $152,869,319 | $219,643,813 | $176,848,065 | $77,365,408 |
| Other Equity Interest | $16,205,769 | $9,952,119 | $8,703,725 | $6,181,245 |
| Gains Losses Not Affecting Retained Earnings | $-1,129,277 | $-1,128,109 | $-977,461 | $-448,441 |
| Other Equity Adjustments | $-1,129,277 | $-1,128,109 | $-977,461 | $-448,441 |
| Retained Earnings | $-212,208,335 | $-139,181,360 | $-85,053,134 | $-71,751,721 |
| Other | ||||
| Ordinary Shares Number | $56,915,542 | $56,915,542 | $56,915,542 | $56,915,542 |
| Share Issued | $56,915,542 | $56,915,542 | $56,915,542 | $56,915,542 |
| Tangible Book Value | $119,327,337 | $186,101,831 | $143,306,082 | $43,823,426 |
| Invested Capital | $152,869,319 | $219,643,813 | $176,848,065 | $77,365,408 |
| Working Capital | $119,873,874 | $192,361,319 | $150,168,163 | $48,311,339 |
| Capital Lease Obligations | $1,464,440 | $1,804,274 | $1,891,860 | $72,405 |
| Total Capitalization | $152,869,319 | $219,643,813 | $176,848,065 | $77,365,408 |
| Additional Paid In Capital | $89,494,335 | $89,494,335 | $50,144,808 | $14,443,536 |
| Capital Stock | $260,506,828 | $260,506,828 | $204,030,126 | $128,940,790 |
| Common Stock | $260,506,828 | $260,506,828 | $204,030,126 | $128,940,790 |
| Long Term Capital Lease Obligation | $1,173,654 | $1,485,461 | $1,680,486 | $42,041 |
| Current Deferred Revenue | $1,706,178 | $935,420 | $1,379,190 | $2,074,039 |
| Current Capital Lease Obligation | $290,786 | $318,813 | $211,375 | $30,363 |
| Current Accrued Expenses | $2,869,321 | $2,245,708 | $1,476,118 | $738,059 |
| Investments And Advances | $12,846 | $14,014 | $16,349 | $16,349 |
| Available For Sale Securities | $12,846 | $14,014 | $16,349 | $16,349 |
| Goodwill | $10,057,223 | $10,057,223 | $10,057,223 | $10,057,223 |
| Net PPE | $1,852,155 | $2,326,287 | $1,875,511 | $72,405 |
| Accumulated Depreciation | $-959,944 | $-497,489 | $-142,473 | $-26,860 |
| Gross PPE | $2,812,099 | $2,823,777 | $2,017,984 | $99,264 |
| Leases | $419,246 | $419,246 | $0 | - |
| Other Properties | $11,678 | $11,678 | - | - |
| Machinery Furniture Equipment | $804,625 | $852,505 | $374,869 | $31,531 |
| Buildings And Improvements | $1,576,550 | $1,540,348 | $1,643,116 | $67,733 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $35,146,560 | $0 | $0 | $46,712,600 |
Fetched: 2026-08-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-60,428,587 | $-55,474,716 | $-28,718,906 | $-22,149,947 |
| Operating Activities | ||||
| Operating Cash Flow | $-60,423,916 | $-54,686,441 | $-28,718,906 | $-22,149,947 |
| Cash Flow From Continuing Operating Activities | $-60,423,916 | $-54,687,609 | $-28,718,906 | $-22,149,947 |
| Operating Gains Losses | $66,565 | $269,765 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-4,671 | $-788,275 | - | - |
| Investing Cash Flow | $-38,542,566 | $-788,275 | $46,712,600 | $-52,068,200 |
| Cash Flow From Continuing Investing Activities | $-38,542,566 | $-788,275 | $46,712,600 | $-52,068,200 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $113,342,285 | $93,274,552 | $44,826,579 |
| Financing Cash Flow | $-394,721 | $113,000,115 | $92,635,757 | $43,947,214 |
| Cash Flow From Continuing Financing Activities | $-394,721 | $113,001,283 | $92,635,757 | $43,947,214 |
| Net Common Stock Issuance | $0 | $113,342,285 | $93,274,552 | $44,826,579 |
| Common Stock Issuance | $0 | $113,342,285 | $93,274,552 | $44,826,579 |
| Net Other Financing Charges | - | $-151,816 | $-522,013 | $-42,041 |
| Other | ||||
| Repayment Of Debt | $-394,721 | $-190,354 | $-116,782 | $-837,323 |
| End Cash Position | $100,920,237 | $200,232,392 | $142,942,892 | $32,313,441 |
| Beginning Cash Position | $200,232,392 | $142,942,892 | $32,313,441 | $62,584,374 |
| Effect Of Exchange Rate Changes | $52,552 | $-238,234 | $0 | $0 |
| Changes In Cash | $-99,364,707 | $57,527,735 | $110,629,451 | $-30,270,933 |
| Net Issuance Payments Of Debt | $-394,721 | $-190,354 | $-116,782 | $-837,323 |
| Net Long Term Debt Issuance | $-394,721 | $-190,354 | $-116,782 | $-837,323 |
| Long Term Debt Payments | $-394,721 | $-190,354 | $-116,782 | $-837,323 |
| Net Investment Purchase And Sale | $-35,034,450 | $0 | $46,712,600 | $-46,712,600 |
| Purchase Of Investment | $-35,034,450 | - | - | - |
| Net Business Purchase And Sale | $-3,503,445 | $0 | $0 | $-5,355,600 |
| Purchase Of Business | $-3,503,445 | $0 | $0 | $-5,355,600 |
| Net PPE Purchase And Sale | $-4,671 | $-788,275 | $0 | - |
| Purchase Of PPE | $-4,671 | $-788,275 | $0 | - |
| Taxes Refund Paid | $0 | $-4,671 | $-3,503 | $-2,336 |
| Interest Received Cfo | $1,894,196 | $1,291,603 | $286,115 | $84,083 |
| Interest Paid Cfo | $-80,579 | $-11,678 | $-23,356 | $-51,384 |
| Change In Working Capital | $474,133 | $-1,497,139 | $4,809,062 | $1,645,451 |
| Change In Other Working Capital | $872,358 | $-461,287 | $-677,333 | $1,689,828 |
| Change In Other Current Assets | $-3,153,100 | $-767,254 | $1,181,829 | $-3,490,599 |
| Change In Payables And Accrued Expense | $2,754,876 | $-268,597 | $4,304,566 | $3,446,222 |
| Change In Payable | $2,754,876 | $-268,597 | $4,304,566 | $3,446,222 |
| Other Non Cash Items | $-1,804,274 | $-1,331,309 | $-253,416 | $71,237 |
| Stock Based Compensation | $6,253,649 | $1,250,730 | $2,521,313 | $2,579,703 |
| Unrealized Gain Loss On Investment Securities | $5,559,967 | $-990,307 | $-22,146,444 | $-13,884,153 |
| Deferred Tax | $0 | $4,671 | $-722,877 | $-3,111,059 |
| Deferred Income Tax | $0 | $4,671 | $-722,877 | $-3,111,059 |
| Depreciation Amortization Depletion | $255,751 | $363,190 | $115,614 | $26,860 |
| Depreciation And Amortization | $255,751 | $363,190 | $115,614 | $26,860 |
| Net Foreign Currency Exchange Gain Loss | $66,565 | $269,765 | $0 | - |
| Net Income From Continuing Operations | $-73,043,325 | $-54,031,297 | $-13,301,413 | $-9,508,350 |
| Sale Of Investment | - | $0 | $46,712,600 | - |
| Change In Prepaid Assets | - | $-461,287 | $-677,333 | $1,689,828 |
| Amortization Cash Flow | - | $0 | $0 | $0 |
| Amortization Of Intangibles | - | $0 | $0 | $0 |
| Depreciation | - | $363,190 | $115,614 | $26,860 |
Fetched: 2026-08-21